These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 36479105)

  • 41. Cutting Edge Genetics: CRISPR/Cas9 Editing of Plant Genomes.
    Soyars CL; Peterson BA; Burr CA; Nimchuk ZL
    Plant Cell Physiol; 2018 Aug; 59(8):1608-1620. PubMed ID: 29912402
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progresses of CRISPR/Cas9 genome editing in forage crops.
    Ul Haq SI; Zheng D; Feng N; Jiang X; Qiao F; He JS; Qiu QS
    J Plant Physiol; 2022 Dec; 279():153860. PubMed ID: 36371870
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CRISPR-Cas9 in genome editing: Its function and medical applications.
    Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
    J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential pitfalls of CRISPR/Cas9-mediated genome editing.
    Peng R; Lin G; Li J
    FEBS J; 2016 Apr; 283(7):1218-31. PubMed ID: 26535798
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions.
    Hazafa A; Mumtaz M; Farooq MF; Bilal S; Chaudhry SN; Firdous M; Naeem H; Ullah MO; Yameen M; Mukhtiar MS; Zafar F
    Life Sci; 2020 Dec; 263():118525. PubMed ID: 33031826
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
    Zhang Y; Sastre D; Wang F
    Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy.
    Song X; Liu C; Wang N; Huang H; He S; Gong C; Wei Y
    Adv Drug Deliv Rev; 2021 Jan; 168():158-180. PubMed ID: 32360576
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A glance at genome editing with CRISPR-Cas9 technology.
    Barman A; Deb B; Chakraborty S
    Curr Genet; 2020 Jun; 66(3):447-462. PubMed ID: 31691023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [CRISPR-Cas9 mediated genome editing in Caenorhabditis elegans].
    Meng X; Zhou H; Xu S
    Sheng Wu Gong Cheng Xue Bao; 2017 Oct; 33(10):1693-1699. PubMed ID: 29082717
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RNA-based gene targeting therapies for human papillomavirus driven cancers.
    Salinas-Montalvo AM; Supramaniam A; McMillan NA; Idris A
    Cancer Lett; 2021 Dec; 523():111-120. PubMed ID: 34627949
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The application of CRISPR-Cas9 gene editing technology in viral infection diseases].
    Yin LJ; Hu SQ; Guo F
    Yi Chuan; 2015 May; 37(5):412-8. PubMed ID: 25998428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Temperature effect on CRISPR-Cas9 mediated genome editing.
    Xiang G; Zhang X; An C; Cheng C; Wang H
    J Genet Genomics; 2017 Apr; 44(4):199-205. PubMed ID: 28412228
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CRISPR-Cas9 technology and its application in haematological disorders.
    Zhang H; McCarty N
    Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Gene Editing Technique in Xenotransplantation.
    Naeimi Kararoudi M; Hejazi SS; Elmas E; Hellström M; Naeimi Kararoudi M; Padma AM; Lee D; Dolatshad H
    Front Immunol; 2018; 9():1711. PubMed ID: 30233563
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CRISPR/Cas9-mediated genome editing in sea urchins.
    Lin CY; Oulhen N; Wessel G; Su YH
    Methods Cell Biol; 2019; 151():305-321. PubMed ID: 30948015
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system.
    Chen Y; Jiang H; Wang T; He D; Tian R; Cui Z; Tian X; Gao Q; Ma X; Yang J; Wu J; Tan S; Xu H; Tang X; Wang Y; Yu Z; Han H; Das BC; Severinov K; Hitzeroth II; Debata PR; Xu W; Fan W; Jin Z; Cao C; Yu M; Xie W; Huang Z; Hu Z; You Z
    Antiviral Res; 2020 Jun; 178():104794. PubMed ID: 32298665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer.
    Azangou-Khyavy M; Ghasemi M; Khanali J; Boroomand-Saboor M; Jamalkhah M; Soleimani M; Kiani J
    Front Immunol; 2020; 11():2062. PubMed ID: 33117331
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CRISPR/Cas System: Recent Advances and Future Prospects for Genome Editing.
    Manghwar H; Lindsey K; Zhang X; Jin S
    Trends Plant Sci; 2019 Dec; 24(12):1102-1125. PubMed ID: 31727474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.